Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 7/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | TK2 | O00142 | 9/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16041280 | 0.86 | CYP3A4 (0.37) | CYP3A4MAPK1TK1ELANEKIF11 | |
| SCHEMBL4408417 | 0.86 | CYP3A4 (0.37) | CYP3A4MAPK1TK1ELANEKIF11 | |
| SCHEMBL18393113 | 0.86 | CYP3A4 (0.37) | CYP3A4MAPK1TK1ELANEKIF11 | |
| SCHEMBL18393204 | 0.86 | CYP3A4 (0.37) | CYP3A4MAPK1TK1ELANEKIF11 | |
| SCHEMBL16062149 | 0.86 | CYP3A4 (0.37) | CYP3A4MAPK1TK1ELANEKIF11 | |
| SCHEMBL19621238 | 0.85 | — | — | |
| SCHEMBL4409735 | 0.75 | CYP3A4 (0.39) | CYP3A4MAPK1TK1ELANEKIF11 | |
| SCHEMBL18393090 | 0.75 | CYP3A4 (0.39) | CYP3A4MAPK1TK1ELANEKIF11 | |
| SCHEMBL16061016 | 0.73 | CYP3A4 (0.37) | CYP3A4MAPK1ELANEKIF11 | |
| SCHEMBL4406431 | 0.71 | CYP3A4 (0.38) | CYP3A4MAPK1ELANEKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4112604-A1 | PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R,5S)-2-FLUORO-4,5-DIHIDROXY-3-HYDROXY-METHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE | Ocuphire Pharma, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |